IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising kidney drug trial halted early – what it means for patients
Disease control TerminatedThis study tested a drug called ALXN2050 in 100 adults with kidney inflammation caused by lupus or IgA nephropathy. The goal was to see if it could reduce protein in the urine, a sign of kidney damage. Participants took the drug or a placebo for up to 50 weeks. The trial was stop…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Kidney disease drug trial stopped early: what we learned
Disease control TerminatedThis study tested a drug called ravulizumab in 123 adults with kidney inflammation caused by lupus or IgA nephropathy. The goal was to see if it could reduce protein in the urine, a sign of kidney damage. The trial was terminated early, but the results may still help researchers …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC